EntreMed Presents Interim Results for Phase 2 Carcinoid T...(NCD andAvastin(R) in a highly vascular t...)

Date:1/28/2008

NCD and Avastin(R), in a highly vascular tumor where antiangiogenic agents, including Avastin(R), have shown activity. By adding Panzem(R) NCD to Avastin(R) therapy, there were no significant differences in the safety profile for these patients as compared to Avastin(R) alone. Additionally, we are encouraged by the length of progression free time that patients have remained on treatment. Once the median progression free survival is established, we will evaluate the data to determine how we should proceed with this combination."

About Carcinoid Tumors

Carcinoids are tumors of neuroendocrine origin. Approximately 85% of carcinoid tumors develop in the gastrointestinal tract between the stomach and the rectum. Approximately half of these originate in the appendix, and may metastasize to the liver, while the remaining half develop in the intestine, rectum and lung. Approximately 6,000-7,000 cases of carcinoid cancer are diagnosed in the U.S. annually and their incidence has been increasing over the past 30 years. It is common for more than one tumor to develop in the small intestine and the presence of a carcinoid tumor increases the probability of other cancers in the digestive system.

Carcinoid tumors often release certain hormones into the bloodstream that cause symptoms such as facial flushing, wheezing, diarrhea, and a fast heartbeat. These symptoms are grouped together and called the "carcinoid syndrome." Carcinoid tumors can release hormonally active peptides into the blood that cause symptoms throughout the body, as contrasted with other tumor types that produce symptoms at the site of the primary tumor or its metastases. Chemotherapy may be indicated in patients with aggressive tumors, progressive liver metastases, partial or complete intestinal obstruction, or severe symptoms uncontrollable by other treatment methods. Standard cytotoxic therapy offers limited benefit to patients with metastatic carcinoid tumors. Neuroendocrine tumors are
'/>"/>

SOURCE EntreMed, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
4. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic